Radiopharmaceutical developer Cerveau Technologies said the U.S. Food and Drug Administration (FDA) has given its MK-6240 tau imaging agent investigational new drug (IND) status.
Cerveau, which licensed the agent from Merck, will now work with partners to study the use of the agent in PET scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs consist of aggregated tau proteins, which are a hallmark of several neurodegenerative diseases, including Alzheimer's disease, the company said.
Clinical studies will determine the ability of MK-6240 to stage disease and quantify the potential effects of therapeutic treatments for neurodegenerative disease, Cerveau said.
